Autres langues Cartesian Therapeutics, Inc.

Actions

RNAC

US8162123025

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 19:50:58 06/10/2026			Varia. 5j.	Varia. 1 janv.
6,930 ^USD	-2,94%		-2,97%	-2,57%

29/09	Cartesian Therapeutics, Inc. annonce de nouvelles données sur le retraitement par Descartes-08 chez des patients atteints de myasthénie généralisée	CI
06/08	Cartesian Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Autres langues

05/10	Cartesian Therapeutics Announces New Employment Inducement Grants
02/10	Cartesian Therapeutics Announces New Employment Inducement Grants
29/09	Cartesian Therapeutics, Inc. Announces Additional Retreatment Data for Descartes-08 in Patients with Myasthenia Gravis
29/09	Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
08/09	Cartesian Therapeutics Announces New Employment Inducement Grants
03/09	Cartesian Therapeutics to Participate in Upcoming Investor Conferences
07/08	Cartesian Therapeutics Announces New Employment Inducement Grants
06/08	Cartesian Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
02/07	Cartesian Therapeutics Announces New Employment Inducement Grants
16/06	The Radoff-JEC Group Highlights Seer Inc.'s and Chairman and CEO Omid Farokhzad, M.D.'s History of Value Destruction
12/06	Cartesian Therapeutics Announces New Employment Inducement Grant
09/06	Cartesian Therapeutics Signs Licensing Agreement With WestGene to Develop Therapies for Autoimmune Diseases
09/06	Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
26/05	Cartesian Therapeutics, Inc. Announces Executive Changes
26/05	Cartesian Therapeutics Expects Topline Data from the Phase 3 Aurora Trial in First Quarter 2027
26/05	Cartesian Therapeutics, Inc. Secures Up to $150 Million of Non-Dilutive Financing from K2 HealthVentures
26/05	Cartesian Therapeutics Secures Up to $150 Million Credit Facility From K2 HealthVentures
26/05	Cartesian Therapeutics Inc - Enters loan and security agreement on May 22 - SEC filing
26/05	Cartesian Therapeutics Inc - phase 3 Aurora topline data in myasthenia gravis expected in 1q27 BLA filing planned mid-2027
26/05	Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
22/05	Cartesian Therapeutics, Inc. announced that it expects to receive $150 million in funding
12/05	Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
04/05	Cartesian Therapeutics Announces New Employment Inducement Grants
30/04	Cartesian Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026